



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	PATENT & TRADEMARK INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,440	03/23/2007	Dominique Bourel	096183-0104	2420

22428 7590 09/10/2010
FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

EXAMINER	
JUEDES, AMY E	
ART UNIT	PAPER NUMBER
1644	

MAIL DATE	DELIVERY MODE
09/10/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice to Comply	Application No. 10576440	Applicant(s) BOUREL ET AL.
	Examiner AMY E. JUEDES	Art Unit 1644
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES		
<p>Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). <input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). <input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). <input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." <input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). <input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). <input type="checkbox"/> 7. Other: <p>Applicant Must Provide:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". <input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. <input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). <p>For questions regarding compliance to these requirements, please contact:</p> <p>For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support Technical Assistance 1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software is Available At www.USPTO.gov</p> <p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>		
/Amy E. Juedes/ Primary Examiner, Art Unit 1644		



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./CONTROL NO. 10576440	FILING DATE 3/23/2007	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION BOUREL ET AL.	ATTORNEY DOCKET NO. 096183-0104
---	--------------------------	---	------------------------------------



EXAMINER
AMY E. JUEDES

ART UNIT 1644	PAPER 20100909
------------------	-------------------

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Web (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)
2. Mailed to:
Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313 1450
Alexandria, VA 22313 1450
3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:
U.S. Patent and Trademark Office
Mail Stop Sequence
Customer Window
Randolph Building
401 Dulaney Street
Alexandria, VA 22314

Any inquiry concerning this communication should be directed to Amy Juedes at telephone number (571)272-4471. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on 571-272-0735

/Amy E. Juedes/
Primary Examiner, Art Unit 1644

Sequence Listing could not be accepted due to errors.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free). .

Reviewer: markspencer

Timestamp: [year=2010; month=1; day=27; hr=10; min=15; sec=52; ms=475;]

<210> 2
<211> 475
<212> PRT
<213> Homo sapiens

<220>

<223> Peptide sequence of double mutant His310-H435Lys.

<400> 2

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
465 470 475

4

1

WASH_6680526.1

The Sequence Listing file must end at the bottom of the last SEQ ID #. There can be no extra information following the last SEQ ID # in the file. Please remove extra information, "4", "1", and "WASH_6680526.1" found at the end of the file, after SEQ ID # 2.

2.

<110> LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES
BIOTECHNOLOGIES

BOUREL, Dominique

GLACET, Arnaud

JORIEUX, Sylvie

STURA, Enrico

DUCANCEL, Frédéric

TEILLAUD, Jean-Luc

<120> USE OF METALLIC CATIONS TO IMPROVE FUNCTIONAL ACTIVITY
OF ANTIBODIES

<130> D 21 711 NT

<140> 10576440

<141> 2010-01-08

<150> PCT/FR2004/002687

<151> 2004-10-20

<150> FR 03 12228

<151> 2003-10-20

<160> 2

<170> PatentIn version 3.3

The sequence listing must be in ASCII text format. This file contains non-ASCII text characters, see numeric identifier <110> the accent marks in the name "Frédéric". Please make all changes necessary to convert this file to ASCII text only.

Application No: 10576440

Version No: 1.0

Input Set:

Output Set:

Started: 2010-01-08 14:18:39.238
Finished: 2010-01-08 14:18:43.864
Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 626 ms
Total Warnings: 4
Total Errors: 13
No. of SeqIDs Defined: 2
Actual SeqID Count: 2

Error code	Error Description
E 355	Empty lines found between the amino acid numbering and the
E 321	No. of Bases conflict, this line has no nucleotides SEQID (2)
E 355	Empty lines found between the amino acid numbering and the
E 321	No. of Bases conflict, this line has no nucleotides SEQID (2)
W 112	Upper case found in data; Found at position(0) SeqId(2)
W 112	Upper case found in data; Found at position(1) SeqId(2)
W 112	Upper case found in data; Found at position(2) SeqId(2)
W 112	Upper case found in data; Found at position(3) SeqId(2)
E 259	Found undefined lettercode; POS (5) SEQID(2)
E 259	Found undefined lettercode; POS (6) SEQID(2)
E 259	Found undefined lettercode; POS (7) SEQID(2)
E 259	Found undefined lettercode; POS (8) SEQID(2)
E 259	Found undefined lettercode; POS (9) SEQID(2)
E 259	Found undefined lettercode; POS (10) SEQID(2)
E 259	Found undefined lettercode; POS (11) SEQID(2)
E 259	Found undefined lettercode; POS (12) SEQID(2)
E 259	Found undefined lettercode; POS (13) SEQID(2)